Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorHans Bahlmann

About this trial

The goal of this clinical trial is to learn whether the addition of spinal analgesia leads to superior recovery in patients undergoing robotic-assisted laparoscopic upper urinary tract surgery under general anesthesia. The main questions it aims to answer are:

* Is the decrease in wellbeing as quantified by the patient-centered outcome scale "Quality of Recovery 15" (QoR-15), from baseline to the first day after surgery (POD 1), at least 8.0 points less in patients receiving spinal analgesia in addition to general anesthesia? * Does spinal analgesia result in improved recovery as quantified by QoR-15 at POD 7, the incidence of postoperative pain at rest and at mobilization, nausea and vomiting, the need for opioid analgesics, time out-of-bed, length of stay and the incidence of complications? * Does spinal analgesia increase workload in the OR, as quantified by time from arrival in the OR to start of surgery? * Does spinal analgesia result in an increased incidence of hypotension and cardiac dysfunction during surgery, as well as an increased incidence of pruritus after surgery?

Participants will be randomized to receive either spinal analgesia with bupivacaine and morphine preoperatively or an intravenous infusion with lidocaine intraoperatively.

QoR-15 and other markers of recovery will be registered using structured interviews preoperatively, at POD1 and POD7. In addition, patients will record pain at rest and at mobilization three times daily in a diary.

In a subgroup of patients advanced hemodynamic parameters will be recorded using pulse-contour analysis before, during and after surgery. Blood samples will also be collected in these patients at fixed intervals and analyzed for amongst others inflammation and cardiac dysfunction.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The patient is scheduled for elective robotic-assisted upper urinary tract surgery at one of the participating hospitals

The patient gives oral and written informed consent after having received oral and writen information about the study

Disqualifiers

The patient has a ASA-class of IV or above

The patient is a minor or declared incompetent, has severe psychiatric disease or is expected not to be able to understand the study information due to severe restrictions in vision, hearing, cognition, reading or Swedish language abilities

The patient is a female who is pregnant or breastfeeding

The patient is a pre-menopausal female who has not undergone sterilisation, hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy, and is not using highly-effective contraception with low user-dependency and cannot provide a negative pregnancy test

Trial design

Design model

Parallel

Treatments tested in this trial

  • spinal analgesia with morphine and bupivacaine

    Drug

    single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery

  • lidocaine infusion

    Drug

    intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t after a bolus of 2 mg/kg (Ideal Body Weight if BMI \> 22, otherwise ABW)

Treatment groups

220 Participants
are divided into 2 treatment groups
Group A: spinal analgesiaExperimental treatment 1 intervention
Group B: lidocaine infusionActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

QoR-15 score at postoperative day 1

Quality of Recovery-15 score ranges from 0 to 150 with 0 reflecting zero wellbeing and 150 reflecting perfect wellbeing. The primary research hypothesis is that the reduction in QoR-15 from baseline before surgery to the first postoperative day (POD 1) is at least 8.0 points less in the morphine spinal group compared to the control group treated with intravenous lidocaine.

Time frame
First day after surgery

Secondary outcomes

1

QoR-15 score preoperatively

Quality of Recovery-15 score ranges from 0 to 150 with 0 reflecting zero wellbeing and 150 reflecting perfect wellbeing.

Time frame
Any time between inclusion and the night before surgery
2

QoR-15 score at postoperative day 7

Quality of Recovery-15 score ranges from 0 to 150 with 0 reflecting zero wellbeing and 150 reflecting perfect wellbeing.

Time frame
Seventh day after surgery
3

Pain (NRS) in rest and during motion 2hrs after arrival to the PACU/ICU/HDU

Numeric Rating Scale ranges from 0 to 10 with 0 reflecting absence of pain and 10 reflecting extreme pain.

Time frame
2 hrs after arrival to the PACU
4

Pain (NRS) on POD 1-3

Numeric Rating Scale ranges from 0 to 10 with 0 reflecting absence of pain and 10 reflecting extreme pain.

Time frame
First, second and third day after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Hans Bahlmann

Lead sponsor

University Hospital, Linkoeping

Sponsor institution

Linkoeping University

Collaborator